07-11-2019
II Studio / Shutterstock.com
The US government is suing Gilead for patent infringement, claiming that the pharmaceutical company has been piggybacking on public research to earn billions from its HIV drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
HIV, PrEP, Truvada, emtricitabine, tenofovir, Gilead, Alexandra Ocasio-Cortez, CDC, Centers for Disease Control and Prevention, Descovy, Alex Azar
Gilead suffers defeat at PTAB in government PrEP battle
06-02-2020
US govt PrEP patents are invalid, Gilead tells court
27-01-2020
Sanders calls on USPTO to block Gilead patent extension
09-12-2019
Gilead challenges US govt patents on HIV drug Truvada
22-08-2019
Gilead claims US government PrEP patents are invalid
20-05-2019
